← Back to all trials
Active Not Recruiting
NCT00935090
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Sex: All
Ages: 18 Years – 120 Years
Healthy volunteers: No
Sponsor: Barbara Ann Karmanos Cancer Institute
Location: Barbara Ann Karmanos Cancer Institute Detroit Michigan
Summary
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Eligibility Criteria
DISEASE CHARACTERISTICS:
* Meets one of the following criteria:
* Histologically confirmed solid tumor or hematologic malignancy
* Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging
PATIENT CHARACTERISTICS:
* Able to lie still in the PET scanner
* Girth and weight must be suitable to enter the gantry
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
* Not specified
Source: ClinicalTrials.gov (NCT00935090). StuddyBuddy aggregates publicly available trial information.
